- Mycoplasma are small, typically between 0.1 to 0.3 micrometers in diameter, - and are pleomorphic, meaning they can vary in shape example: spherical, ovoid, - or even branched under a microscope. This feature allows them to squeeze through - tight spaces and avoid some antibiotics, especially those that target cell walls, - like penicillin. They are unique in that they lack a cell wall, unlike most + Mycoplasma are small, typically between 0.1 to 0.3 + micrometers in diameter, and are pleomorphic, meaning they can vary in + shape example: spherical, ovoid, or even branched under a microscope. + This feature allows them to squeeze through tight spaces and avoid + some antibiotics, especially those that target cell walls, like + penicillin. They are unique in that they lack a cell wall, unlike most bacteria, which gives them unusual flexibility and resilience.
- Mycoplasma pneumoniae infections have been on the - rise in Europe, including Norway, following a recent trend of increased - cases across multiple countries (Figure 1). Known for - causing respiratory infections such as "walking pneumonia",{" "} - Mycoplasma pneumoniae primarily affects children and young adults - and often results in mild symptoms like a persistent cough and fever. - Recently, however, some regions have reported more severe symptoms and a - notable rise in hospital visits due to complications, particularly in - younger children under age five, a demographic not typically as impacted - by Mycoplasma infections in the past. + + Mycoplasma pneumoniae + {" "} + infections have been on the rise in Europe, including Norway, + following a recent trend of increased cases across multiple countries{" "} + (Figure 1). Known for causing respiratory infections + such as "walking pneumonia", Mycoplasma pneumoniae{" "} + primarily affects children and young adults and often results in mild + symptoms like a persistent cough and fever. Recently, however, some + regions have reported more severe symptoms and a notable rise in + hospital visits due to complications, particularly in younger children + under age five, a demographic not typically as impacted by Mycoplasma + infections in the past.
- In Norway, public health authorities are closely monitoring the situation - and coordinating with European and U.S. health agencies to understand the - potential for antibiotic resistance in these cases. While Mycoplasma pneumoniae - infections are usually treated with macrolides, - resistance to these antibiotics has been observed, particularly in regions - like Asia and occasionally in the United States and Europe. Norway's - health services are advising vigilance in monitoring symptoms and have - issued guidance on treatment practices to address this emerging resistance concern. + In Norway, public health authorities are closely monitoring the + situation and coordinating with European and U.S. health agencies to + understand the potential for antibiotic resistance in these cases. + While Mycoplasma pneumoniae + infections are usually treated with macrolides, resistance to these + antibiotics has been observed, particularly in regions like Asia and + occasionally in the United States and Europe. Norway's health + services are advising vigilance in monitoring symptoms and have issued + guidance on treatment practices to address this emerging resistance + concern.
- +- There is growing concern about resistance to macrolide antibiotics (e.g., azithromycin), - the first-line treatment for Mycoplasma pneumoniae. + There is growing concern about resistance to macrolide antibiotics + (e.g., azithromycin), the first-line treatment for{" "} + Mycoplasma pneumoniae.
-- First-Line Antibiotics: Macrolides (e.g., azithromycin, erythromycin) are typically prescribed. + First-Line Antibiotics: Macrolides (e.g., azithromycin, erythromycin) + are typically prescribed.
- +